<p>For decades, the most powerful cholesterol-lowering treatments — PCSK9 inhibitors — have required injections every two to four weeks. Effective, yes. But the injection requirement meant lower patient compliance, clinic visits, and a significant barrier to treatment.</p>
<p>Now, a large Phase 3 trial published in the <em>New England Journal of Medicine</em> has shown that a once-daily pill called <strong>enlicitide</strong> can match that same power — taken at home, every morning, like a vitamin.</p>
<h2>The Numbers Are Remarkable</h2>
<p>The CORALreef Lipids trial enrolled <strong>2,909 adults</strong> with or at high risk for heart disease. Results at 24 weeks:</p>
<ul> <li><strong>55.8% reduction in LDL-C</strong> (bad cholesterol) versus placebo</li> <li>Post-hoc analysis: <strong>59.7% reduction</strong></li> <li><strong>67.5% of patients</strong> achieved at least 50% LDL reduction AND dropped below the target of 55 mg/dL</li> <li>Only <strong>1.2%</strong> of the placebo group achieved the same</li> <li>Safety profile comparable to placebo — no serious additional risks observed</li> </ul>
<p>At one year, the reductions held: 47.6% below baseline (52.4% in post-hoc analysis).</p>
<h2>Why This Matters</h2>
<p>Cardiovascular disease kills more people globally than any other cause. Despite the availability of statins, tens of millions of people can't achieve safe LDL levels — either because statins aren't strong enough, or because side effects make them unworkable.</p>
<p>Injectable PCSK9 inhibitors like alirocumab and evolocumab exist, and they work. But compliance with injections is much lower than with pills. Converting an injection therapy into a daily pill isn't just convenient — it's potentially <strong>life-saving</strong> at scale.</p>
<p>"This could fundamentally change the landscape for patients who need more aggressive cholesterol management," said Dr. James Januzzi of Harvard Medical School, one of the trial investigators.</p>
<h2>What's Next</h2>
<p>Merck has submitted enlicitide for FDA review. An ongoing cardiovascular outcomes trial — CORALreef Outcomes — will determine whether the LDL reductions translate into fewer heart attacks and strokes, with results expected by late 2029.</p>
<p>But the evidence from Phase 3 is already compelling. Cardiologists are watching this closely.</p>
<p><em>Source: New England Journal of Medicine, March 2026 | Merck | CORALreef Lipids Trial | American Heart Association</em></p>
